IC50: 0.58 μM (SRPK1)[1]
SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1].
SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1].
SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1].
Western Blot Analysis[1]
| Cell Line: | ARPE-19 cell line |
| Concentration: | 10 μM |
| Incubation Time: | 2 hours |
| Result: | Blocked EGF-induced phosphorylation of SRSF1 and SRSF2. |
SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1].
SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1].
| Animal Model: | C57/B6 mice with laser-induced CNV[1] |
| Dosage: | 10 ng |
| Administration: | Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 |
| Result: | Significantly reduced neovascular growth compared with saline-injected controls. |
| Animal Model: | Norway Brown rats with laser-induced choroidal neovascularization[1] |
| Dosage: | 25 ng (10 ng/uL) |
| Administration: | Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 |
| Result: | Significantly reduced the CNV area compared with saline injected controls. |